Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Confirmation of Results Date
Analyst and Investor Presentations
Manchester, UK 6 August 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, confirms that the full year results for the year ended 31 March 2021 will be announced on Wednesday 11 August 2021.
Analyst presentation
A briefing open to analysts will take place remotely via video conference call on Wednesday 11 August 2021 at 9.30am. To register and for more details of this call please contact Walbrook PR on yourgene@walbrookpr.com
Investor presentation
A live presentation via the Investor Meet Company will be delivered by Lyn Rees CEO and Barry Hextall CFO on Thursday 12 August 2021 at 2:00pm BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Yourgene Health PLC via:
https://www.investormeetcompany.com/yourgene-health-plc/register-investor
Investors who already follow Yourgene Health PLC on the Investor Meet Company platform will automatically be invited.
| Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 | |||
| Barry Hextall, Chief Financial Officer | | |||
| Joanne Cross, Director of Marketing | | |||
| | | |||
| Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 | |||
| Liam Murray / James Caithie / Ludovico Lazzaretti |
| |||
| Singer Capital Markets (Joint Corporate Broker) | Tel: +44 (0)20 7496 3000 | |||
| Aubrey Powell / Tom Salvesen / George Tzimas | | |||
| | | |||
| Stifel Nicolaus Europe Limited (Joint Corporate Broker) | Tel: +44 (0)20 7710 7600 | |||
| Nicholas Moore / Matthew Blawat / Ben Maddison | | |||
| | | |||
| Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com | |||
| Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / Mob: 07584 391 303 | |||
| | | |
| |
About Yourgene Health plc
Yourgene Health is an international molecular diagnostics group which develops and commercialises genomic services and technologies. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and infectious diseases. The Group's flagship in vitro diagnostic products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping.
Yourgene has a range of innovative DNA sample preparation platforms, powered by Ranger® Technology, the Yourgene LightBench® and Yourgene QS250, ideal for cell-free DNA applications in NIPT and oncology including liquid biopsy.
Yourgene Genomic Services is a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
Yourgene Health is headquartered in Manchester, UK with facilities in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". Follow us on LinkedIn and Twitter.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
